Search
Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team and the ECOG-ACRIN Cancer Research Group, have found that abbreviated breast magnetic resonance imaging (MRI) detected more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue.
Practical tips for caregivers helping an older relative or friend make decisions about cancer treatment.
A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.
By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.
For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.
Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.
In 1971, Richard Nixon launched a “war on cancer.” It’s still raging.
New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
The insights lay the groundwork for earlier diagnosis and better treatment of the disease.